Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [14896]

ASCO 2022: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

ASCO 2022: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

ASCO 2022: Autologous stem cell transplant showed improved progression-free survival in newly diagnosed multiple myeloma patients

ASCO 2022: Autologous stem cell transplant showed improved progression-free survival in newly diagnosed multiple...

ASCO 2022: Combination regimen improves overall survival in a type of newly diagnosed metastatic colorectal cancer

ASCO 2022: Combination regimen improves overall survival in a type of newly diagnosed metastatic colorectal cancer

ASCO 2022: Novel antibody-drug conjugate doubles progression-free survival in metastatic breast cancer with low HER2 expression levels

ASCO 2022: Novel antibody-drug conjugate doubles progression-free survival in metastatic breast cancer with low...

$ASCO 2022: High-dose ifosfamide demonstrated as a standard of care for recurrent and primary refractory ewing sarcoma$

ASCO 2022: High-dose ifosfamide demonstrated as a standard of care for recurrent and primary refractory ewing...

ASCO 2022: Lung cancer therapy could help patients live longer

ASCO 2022: Lung cancer therapy could help patients live longer

ASCO 2022: Immunotherapy before surgery associated with improved survival for soft-tissue sarcoma

ASCO 2022: Immunotherapy before surgery associated with improved survival for soft-tissue sarcoma

ASCO 2022: Novel agent increases PFS for patients with the most common type of advanced breast cancer

ASCO 2022: Novel agent increases PFS for patients with the most common type of advanced breast cancer

ASCO 2022: Liquid biopsy can help identify the need for adjuvant therapy in stage II colon cancer

ASCO 2022: Liquid biopsy can help identify the need for adjuvant therapy in stage II colon cancer

ASCO 2022: Ibrutinib improves progression-free survival by 50% for older patients with newly diagnosed mantle cell lymphoma

ASCO 2022: Ibrutinib improves progression-free survival by 50% for older patients with newly diagnosed mantle cell...

More from ecancer